StratifAI has raised €12.5 million in an oversubscribed funding round to advance the clinical validation of its AI-powered biomarker platform Polaris™, targeting the unmet needs in cancer diagnostics.
Target Information
StratifAI, a Berlin-based biotechnology firm focused on precision oncology, has successfully raised €12.5 million in an oversubscribed funding round aimed at accelerating the clinical validation of its innovative AI-based biomarker discovery platform, Polaris™. This funding initiative is pivotal in enhancing StratifAI's capacity to pioneer advancements in cancer diagnostics by harnessing multimodal AI technology to identify and validate cancer biomarkers.
The company’s flagship product, Polaris™ Breast, is designed to evaluate the risk of breast cancer recurrence by analyzing digitized histology data. With this recent capital influx, StratifAI aims to expedite clinical trials and regulatory processes both in Europe and the United States, thus enhancing its competitive positioning in the oncology market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The oncology diagnostics market in Germany is rapidly evolving, facilitated by technological advancements and an increasing emphasis on personalized medicine. The integration of artificial intelligence in healthcare has op
Similar Deals
Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners, Bayern Kapital, High-Tech Gründerfonds, PhiFund Ventures → SciRhom GmbH
2024
Picus Capital
invested in
StratifAI
in 2025
in a Series A deal
Disclosed details
Transaction Size: $13M